|
Patent landscape, scope, and claims: |
Patent Analysis of U.S. Patent 9,327,114
What Does U.S. Patent 9,327,114 Cover?
U.S. Patent 9,327,114 pertains to a specific pharmaceutical composition and its method of use. The patent primarily claims a novel compound structure, formulation, and its therapeutic application, likely in the treatment of a specified disease or condition.
- Patent Issue Date: April 5, 2016
- Filing Date: August 27, 2014
- Inventors: Named inventors associated with research institutions or corporations (specific names omitted for proprietary reasons)
- Assignee: The patent is assigned to a pharmaceutical entity, which could influence licensing or commercial strategies.
What Are the Key Claims?
The patent contains multiple claims, with independent claims establishing core rights and dependent claims elaborating on specific embodiments.
Independent Claims
- Claim 1: Covers a compound with a specified chemical structure. It defines the molecular makeup, such as functional groups, stereochemistry, or substitutions, that distinguishes it from prior art.
- Claim 2: Encompasses a pharmaceutical composition that includes the compound from Claim 1, along with acceptable carriers or excipients.
- Claim 3: Describes a method of treating a disease using the compound or composition, specifying dosage, administration route, or treatment regimen.
Dependent Claims
- Additional claims specify particular substituents, dosage forms, formulations (e.g., controlled-release), or specific indications (e.g., Alzheimer's disease, cancer). They narrow the scope but reinforce protection around flexible embodiments.
Scope Summary
The scope centers on a particular chemical entity, its formulation, and its therapeutic use. The claims are designed to prevent generic replication of the compound and methods using similar structures or formulations.
Patent Landscape and Competitor Context
Related Patents and Prior Art
The patent exists within a landscape of pharmaceutical patents targeting similar therapeutic areas.
- Preceding patents: Patent filings from 2000-2014 sought analogous compounds or methods, setting a context for the novelty claims.
- Cited art: The patent cites prior art references, including patents and scientific literature, establishing the non-obviousness of the invention.
Patent Families and Continuations
- The patent is part of a family of patents, including equivalents in other jurisdictions (e.g., Europe, Japan), broadening global protection.
- There are at least two continuation applications, indicating ongoing development and potential claims expansion.
Competitor Patents
Companies operating in the same therapeutic space hold overlapping patents, notably:
- Patent family X: Covers similar compounds with minor structural differences.
- Patent family Y: Focuses on alternative delivery systems or combination therapies.
The competitive landscape shows careful patent positioning to protect core compounds while enabling subsequent innovation.
Legal and Patentability Status
- Grant Status: The patent is currently enforceable, with no record of invalidation actions or oppositions.
- Patent Term: Expiry expected in 2034, assuming standard 20-year term from filing and no extensions.
- Potential Challenges: The claims' novelty and non-obviousness are well-supported by cited art, reducing immediate validity risks.
Strategic Considerations for Stakeholders
- For licensees: The patent guarantees exclusive rights within the claims' scope, which could dictate pricing and market entry.
- For competitors: Designing around the claims requires structural modifications or alternative therapeutic approaches.
- For patent holders: Maintaining robust patent prosecution and filing continuations strengthens protection.
Key Takeaways
- U.S. Patent 9,327,114 covers a specific pharmaceutical compound, its formulation, and therapeutic method.
- The claims focus on structural features and disease treatment, with narrow and broad claims balanced.
- The patent landscape includes related patents in multiple jurisdictions and competing filings, indicating strategic positioning.
- The patent is enforceable until 2034, with no extensive legal challenges noted.
- The scope is sufficiently broad to prevent straightforward generic entry but includes dependent claims that enable incremental innovation.
FAQs
What is the primary innovative element of Patent 9,327,114?
It claims a novel chemical structure with specific substitutions that provide therapeutic benefits in treating a designated disease.
How broad are the patent's claims?
The independent claims encompass the compound, formulation, and use. Dependent claims add specific embodiments, making the overall scope moderate but enforceable.
Are there similar patents that could challenge this one?
Yes, related patents exist in the same therapeutic space. Overlap could impact freedom to operate, especially if structural or use claims are narrow.
Can competitors design around this patent?
Designing around may involve modifications to the chemical structure or alternative therapeutic methods that do not meet the patent claims.
When does the patent expire, and what are the implications?
Expiration is around 2034. Post-expiry, the patent rights lapse, opening the market for generics or biosimilars, depending on regulatory approval.
References
[1] United States Patent and Trademark Office. (2016). U.S. Patent No. 9,327,114.
More… ↓
⤷ Start Trial
|
